Tirzepatide is a new generation drug that targets GLP-1R/GIPR for the treatment of type 2 diabetes.
Tirzepatide consists of 17 types of 39 amino acids (including 37 coded amino acids and 2 non-coded amino acids). In November 2023, Tirzepatide was approved by the FDA for weight management in adult obese patients and overweight groups. This indication has been applied for and accepted for marketing in China. In addition, the indications under investigation for Tirzepatide also include NASH (non-alcoholic steatohepatitis), heart failure, etc.
Our company adopts solid-phase synthesis/liquid-phase synthesis combined method of production, combined with continuous flow synthesis technology, to obtain high-quality bulk Tirzepatide powder with considerable yield.
The structure of Tirzepatide contains a side chain similar to that of Semaglutide. Compared with Semaglutide, Tirzepatide has a greater impact on blood sugar and body weight.
Tirzepatide can selectively bind and activate GIP and GLP-1 receptors, bind albumin and extend half-life. Tirzepatide enhances first- and second-phase insulin secretion and decreases glucagon levels, both in a glucose-dependent manner.
Tirzepatide clinical trials
Animal experiments show that Tirzepatide and Semaglutide have similar hypoglycemic mechanisms and better weight loss effects. Phase II clinical trials show that Tirzepatide is superior to Semaglutide in both blood sugar and weight loss effects.
The results of the phase III clinical study SURMOUNT-2 showed that subjects taking 10mg and 15mg of Tirzepatide reduced their average body weight by 13.4% and 15.7% respectively, while subjects in the placebo group reduced their weight by 3.3%.
Tirzepatide dosage for weight loss
1. The recommended starting dose is 2.5 mg subcutaneously once a week. Start treatment with the 2.5 mg dose, but not for glycemic control.
2. After 4 weeks, increase the dose to 5 mg and give it a weekly subcutaneous injection.
3. If additional glycemic control is needed, increase the current dose to 2.5 mg at least after 4 weeks.
4. The maximum dose is 15 mg, subcutaneous injection once a week.
Buy tirzepatide online
The World Obesity Federation estimates the development of obesity in various countries and regions around the world from 2020 to 2035. The report states: "It is expected that more than 4 billion people worldwide will be overweight or obese in 2035, accounting for more than half of the global population, and the prevalence of obesity will increase from 14% in 2020 to 24%.
Reducing caloric intake and increasing exercise are recommended approaches for obesity management, but their overall effectiveness is limited by two factors. First, the weight loss effect of lifestyle intervention is average, with less than 20% of people able to lose more than 15% of their weight. Second, weight loss achieved through lifestyle intervention usually restores one-third of the body weight within a year and gradually recovers over time.
What are the key words in the pharmaceutical market in the past two years? "Weight loss pills" are an essential one.
A new weight loss drug based on a GLP-1 receptor agonist has been approved for marketing and can support weight loss. In people who are obese or overweight but do not have diabetes, semaglutide can reduce body weight by 15% over 2 years.
People who were obese or overweight but did not have diabetes experienced a 20.9% weight loss after 72 weeks of Tizepatide treatment, which was accompanied by a reduction in cardiometabolic risk factors.
